<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671290</url>
  </required_header>
  <id_info>
    <org_study_id>19-10</org_study_id>
    <nct_id>NCT04671290</nct_id>
  </id_info>
  <brief_title>Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae</brief_title>
  <acronym>TEMO-BLSE</acronym>
  <official_title>Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae: a Multicenter Case-control Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APHP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorbonne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopitaux Civils de Colmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Annecy Genevois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E&#xD;
      UTI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were&#xD;
      enrolled in a multicenter retrospective case-control study. Cases were treated with&#xD;
      temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received&#xD;
      carbapenem over the effective antibiotic therapy duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical cure</measure>
    <time_frame>Day 14 (End of antibiotic treatment according to national recommendations)</time_frame>
    <description>Number of patient in clinical cure is defined as the resolution of fever and symptoms of UTI present at antibiotic initiation (and no new symptoms) and the absence of clinical or microbiological failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic of fever defervescence</measure>
    <time_frame>Baseline (day 0), day 3, day 7, day 14</time_frame>
    <description>Median fever calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>Baseline (day 0), day 3, day 7, day 14</time_frame>
    <description>White blood cells (WBC) count (/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>Baseline (day 0), day 3, day 7, day 14</time_frame>
    <description>CRP level (mg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>3 months after UTI diagnosis</time_frame>
    <description>Mean duration of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of UTI</measure>
    <time_frame>3 months after antibiotic therapy initiation</time_frame>
    <description>Number of patient with a new UTI diagnosis after the end of antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss to follow-up, re-hospitalization, and mortality (safety endpoints)</measure>
    <time_frame>3 months after antibiotic therapy initiation</time_frame>
    <description>Number of loss to follow-up, re-hospitalization, and mortality</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">144</enrollment>
  <condition>Urinary Tract Infection Bacterial</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Any intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive adults hospitalized in participating sites for a definite diagnosis of UTI due&#xD;
        to an ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems, were eligible&#xD;
        for the study if they provided a non-opposition form for retrospective data collection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Diagnosis of UTI defined by at least two of the following symptoms :chills,temperature&#xD;
             &gt;38°C (fever), flank or pelvic pain, nausea or vomiting, dysuria, urinary frequency,&#xD;
             or urinary urgency, costovertebral angle tenderness on physical examination&#xD;
&#xD;
          -  Positive urine culture with ≥ 103 CFU/mL of a single strain of ESBL-E&#xD;
&#xD;
          -  Confirmed ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multibacterial infection&#xD;
&#xD;
          -  Opposition to data collection according to GDPR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu LAFAURIE, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP, St Louis Hospital</affiliation>
  </overall_official>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

